0000000000213406

AUTHOR

Peter Schlattmann

showing 5 related works from this author

PaFLO: Pazopanib with 5-fluorouracil, leucovorin, and oxaliplatin (FLO) as first-line treatment in advanced gastric cancer: A randomized phase II stu…

2012

TPS4138 Background: VEGF inhibition in gastric cancer shows promising improvement of remission rate and progression-free survival (Ohtsu et al., JCO 2011). Pazopanib is an orally available tyrosine kinase inhibitor (TKI) selectively inhibiting VEGFR-1, -2, -3, c-kit and PDGFR. It is approved for treating renal cell cancer. A phase-I trial showed good tolerability of pazopanib with full-dose FOLFOX in solid tumors (Brady et al., ASCO, 2009). FLO is a widely used combination for advanced gastric cancer recommended in national guidelines. Methods: 75 Patients with HER-2-negative locally advanced or metastatic adenocarcinoma of the stomach or the gastro-esophageal junction will be randomized i…

OncologyCancer Researchmedicine.medical_specialtybiologybusiness.industryVEGF receptorsPhases of clinical researchCancerAdvanced gastric cancermedicine.diseaseOxaliplatinFirst line treatmentPazopanibOncologyFluorouracilInternal medicinebiology.proteinmedicinebusinessmedicine.drugJournal of Clinical Oncology
researchProduct

Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (Icatibant)

2006

Background In hereditary angioedema, bradykinin is assumed to be the most important mediator of edema formation. Objective To assess whether the selective bradykinin receptor-2 antagonist Icatibant is effective in acute edema attacks of hereditary angioedema. Methods In this uncontrolled pilot study, 15 patients with 20 attacks were treated with Icatibant. The attacks were analyzed by using a standardized and validated visual analog scale measurement and compared with historical data of untreated attacks. Plasma bradykinin concentration was measured before and 4 hours after intravenous Icatibant treatment. Results Symptom intensity decreased within 4 hours after administration of Icatibant;…

AdultMaleImmunologyBradykininPilot ProjectsBradykininchemistry.chemical_compoundEcallantideIcatibantBradykinin B2 Receptor AntagonistsHumansImmunology and AllergyMedicineAngioedemaBradykinin receptorBradykinin B2 Receptor AntagonistsAngioedemabusiness.industryGenetic Diseases InbornMiddle Agedmedicine.diseasechemistryAnesthesiaAcute DiseaseHereditary angioedemaFemalemedicine.symptomB2 Bradykinin Receptorbusinessmedicine.drugJournal of Allergy and Clinical Immunology
researchProduct

Aspirin use and breast cancer risk: a meta-analysis and meta-regression of observational studies from 2001 to 2005

2007

Purpose To examine the recent epidemiological studies on aspirin use and breast cancer risk published from 2001 to 2005 within a meta-analysis, to investigate reasons for heterogeneity between the individual studies and to analyse a dose-response-relationship considering frequency and duration of use. Methods We systematically searched for cohort-studies and case-control-studies from 2001–2005, which evaluated the association between aspirin and breast cancer risk. We calculated a pooled estimate for the relative risk (RR) and investigated reasons for heterogeneity between the individual studies and analysed a dose-response-relationship using random effects mixed models. Results We identifi…

RiskOncologymedicine.medical_specialtyEpidemiologyBreast NeoplasmsDrug Administration ScheduleBreast cancerInternal medicineEpidemiologymedicineHumansPharmacology (medical)Meta-regressionAspirinModels StatisticalAspirinDose-Response Relationship Drugbusiness.industryAnti-Inflammatory Agents Non-SteroidalReproducibility of Resultsmedicine.diseaseRandom effects modelSurgeryMeta-analysisRelative riskRegression AnalysisFemaleObservational studyControlled Clinical Trials as Topicbusinessmedicine.drugPharmacoepidemiology and Drug Safety
researchProduct

Meta-Analysis in Epidemiology

2007

The use of meta-analyses in order to synthesise the evidence from epidemiological studies has become more and more popular recently. It has been estimated by Egger et al. (1998) that from articles retrieved by MEDLINE with the medical subject heading (MeSH) term “meta-analysis” some 33% reported results of a meta-analysis from randomised clinical trials and nearly the same proportion (27%) were from observational studies, including 12% papers in which the aetiology of a disease was investigated. The remaining papers include methodological publications or review articles. Reasons for the popularity of meta-analyses are the growing information in the scientific literature and the need of time…

Clinical trialmedicine.medical_specialtyFamily medicineMeta-analysisPublic healthEpidemiologymedicineMEDLINEObservational studyPublication biasScientific literaturePsychology
researchProduct

Jillian Russyll (AKA Jill) Tate

2018

030213 general clinical medicinemedia_common.quotation_subjectBiochemistry (medical)Clinical BiochemistryArt historyGeneral MedicineArt030204 cardiovascular system & hematology03 medical and health sciencesLaboratory Medicine0302 clinical medicineRicordoRicordo Laboratory Medicine RememberAKARemembermedia_commonClinical Chemistry and Laboratory Medicine (CCLM)
researchProduct